Education
About Us
Working with TipRanks
Follow Us
Supernus Pharmaceuticals (SUPN)
NASDAQ:SUPN
SUPN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$25.53 - $40.28
Previous CloseN/A
Volume41.90K
Average Volume (3M)761.95K
Market Cap
$1.80B
Enterprise Value$1.38B
Total Cash (Recent Filing)$75.05M
Total Debt (Recent Filing)$41.53M
Price to Earnings (P/E)24.4
Beta0.79
Next Earnings
May 13, 2025EPS Estimate
0.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.32
Shares Outstanding55,814,495
10 Day Avg. Volume857,398
30 Day Avg. Volume761,945
Financial Highlights & Ratios
PEG Ratio0.00472
Price to Book (P/B)N/A
Price to Sales (P/S)2.72
Price to Cash Flow (P/CF)10.10
P/FCF Ratio10.10
Enterprise Value/Market Cap0.77
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit2.37
Enterprise Value/Ebitda8.34
Forecast
1Y Price Target
$38.80Price Target Upside20.68% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
---
Supernus Pharmaceuticals News
PremiumCompany Announcements
Supernus Pharmaceuticals’ Earnings Call Highlights Growth and Challenges
PremiumCompany Announcements
Supernus Pharmaceuticals Reports Strong 2024 Financial Growth
PremiumCompany Announcements
Supernus Pharmaceuticals Updates Executive Compensation Packages---
Bulls Say, Bears Say
Bulls Say
FDA ApprovalThe FDA has approved Onapgo (SC apomorphine pump) to treat OFF episodes in Parkinson's disease.
Market OpportunityThe large ADHD market can support multiple branded non-stimulants, suggesting room for Qelbree's growth.
Patent ExtensionQelbree's '338 patent has been extended by 2 years to 2035, which buys time for management to introduce more pipeline assets.
Bears Say
Clinical Trial AnalysisThe trial for SPN-820 is on 'pause' as the company continues to analyze more data from the study.
Clinical Trial ChallengesDisappointing Phase 2b data from SPN-820 in treatment-resistant patients led to a downgrade of the stock rating.
Data DifferentiationNo subgroup profiles or specific data trends stood out in the SPN-820 trial, indicating potential challenges in differentiating treatment effects.
---
Ownership Overview
4.12% Insiders
31.78% Mutual Funds
28.93% Other Institutional Investors
3.55% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SUPN FAQ
What was Supernus Pharmaceuticals’s price range in the past 12 months?
Supernus Pharmaceuticals lowest stock price was $25.53 and its highest was $40.28 in the past 12 months.
What is Supernus Pharmaceuticals’s market cap?
Supernus Pharmaceuticals’s market cap is $1.80B.
When is Supernus Pharmaceuticals’s upcoming earnings report date?
Supernus Pharmaceuticals’s upcoming earnings report date is May 13, 2025 which is in 51 days.
How were Supernus Pharmaceuticals’s earnings last quarter?
Supernus Pharmaceuticals released its earnings results on Feb 25, 2025. The company reported $0.746 earnings per share for the quarter, beating the consensus estimate of $0.52 by $0.226.
Is Supernus Pharmaceuticals overvalued?
According to Wall Street analysts Supernus Pharmaceuticals’s price is currently Undervalued.
Does Supernus Pharmaceuticals pay dividends?
Supernus Pharmaceuticals does not currently pay dividends.
What is Supernus Pharmaceuticals’s EPS estimate?
Supernus Pharmaceuticals’s EPS estimate is 0.36.
How many shares outstanding does Supernus Pharmaceuticals have?
Supernus Pharmaceuticals has 55,814,495 shares outstanding.
What happened to Supernus Pharmaceuticals’s price movement after its last earnings report?
Supernus Pharmaceuticals reported an EPS of $0.746 in its last earnings report, beating expectations of $0.52. Following the earnings report the stock price went down -2.743%.
Which hedge fund is a major shareholder of Supernus Pharmaceuticals?
Currently, no hedge funds are holding shares in SUPN
---
Supernus Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$38.80 (20.68% Upside)
$38.80 (20.68% Upside)
Blogger Sentiment
Bullish
SUPN Sentiment 80%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 261.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $505.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 15.2%
Last 30 Days ▼ 15.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-8.58%
12-Months-Change
Fundamentals
Return on Equity
7.55%
Trailing 12-Months
Asset Growth
6.52%
Trailing 12-Months
Company Description
Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. Its neurology portfolio consists of Oxtellar XR and Trokendi XR, which treats patients with epilepsy. The firm also develops product candidates for the treatment of impulsive aggression and for the treatment of attention deficit hyperactivity disorder. The company was founded by Jack A. Khattar on March 30, 2005 and is headquartered in Rockville, MD.
---
SUPN Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong growth in core products and financial performance, FDA approvals, and a robust cash position. However, challenges include declines in legacy product sales, unfavorable study results for SPN-820, and conservative 2025 guidance. The positive aspects slightly outweigh the negative trends.Read More>---
SUPN Stock 12 Month Forecast
Average Price Target
$38.80
▲(20.68% Upside)
Technical Analysis
ACADIA Pharmaceuticals
―
Jazz Pharmaceuticals
―
Neurocrine
―
Heron Therapeutics
―
Axsome Therapeutics
―
Best Analysts Covering SUPN
1 Year
---